abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

1 Nov 2008

Author:
Oxfam International

Ending the R&D Crisis in Public Health: Promoting pro-poor medical innovation

Insufficient resources are dedicated to developing the new vaccines, diagnostics, and medicines that can address health needs in developing countries…Pharmaceutical companies do not prioritise R&D to address diseases of the developing world, due to lower financial returns…the WTO TRIPS Agreement…failed to boost R&D in pharmaceuticals to satisfy the needs of developing countries, and it provides monopolies to pharmaceutical companies that result in unaffordable prices for medicine…Three main barriers hinder progress:…Insufficient financing…; lack of bold and creative thinking about incentive mechanisms…; absence of coordination concerning R&D…[refers to Abbott, Bristol-Myers Squibb, Eli Lilly, Genzyme, GlaxoSmithKline, Lupin, Ranbaxy, Roche, Wyeth]